Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00881322
Other study ID # GAN-2008
Secondary ID
Status Completed
Phase N/A
First received April 13, 2009
Last updated September 29, 2009
Start date June 2008
Est. completion date September 2008

Study information

Verified date September 2009
Source Miami Research Associates
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of Digestive Advantageā„¢ Gas Defense formula, a probiotic dietary supplement. The study will last approximately four weeks, and subjects will be seen at a screening/randomization visit, and two follow-up visits.

Study procedures will include administering questionnaires for assessment of the study product's effect on intestinal gas symptoms and quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Subject is 18-75 years of age.

- Subject self-reports at least one of the following symptoms after eating a meal or snack:

- Abdominal pain/cramps

- Distended feeling/bloating

- Flatulence/gas

- Subject is in otherwise general good health as determined by physical exam and medical history.

- Subject is willing and able to comply with the protocol.

- Female subjects not defined as post-menopausal (excluding hysterectomized and post bilateral tubal ligations) must use a reliable method of birth control as defined within this protocol.

- Subject is able to understand and sign the informed consent (English or Spanish) to participate in the study.

Exclusion Criteria:

- Subject has any of the following medical conditions:

- active heart disease

- renal or hepatic impairment/disease

- Type I or II diabetes

- psychiatric disorders (hospitalized within the past one year)

- bipolar disorder

- Parkinson's disease

- unstable thyroid disease

- immune disorder (such as HIV/AIDS)

- any medical condition deemed exclusionary by the Principal Investigator (PI)

- Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.

- Subject has had any stomach or intestinal surgery (i.e. gastric bypass).

- Subject is currently taking antibiotics (or any drug that significantly interferes with bacterial flora) or has taken antibiotics within the 30 days prior to screening/enrollment.

- Subject is currently taking or has used in the past 30 days probiotics or prebiotics.

- Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).

- Subject is currently taking any medication deemed exclusionary by PI.

- Subject has a history of or currently has any gastrointestinal disorders or inflammatory bowel conditions such as Crohn's disease, short bowel, or ulcerative colitis. Subjects may not have a diagnosis, be seeing a doctor, or taking prescription medication(s) for Irritable Bowel Syndrome (IBS).

- Subject has constipation defined as less than three spontaneous bowel movements per week.

- Subject is lactose intolerant (self-professed or diagnosed).

- Subject uses any of the following classification of GI medications two or more times per week: anti-spasmodics, motility agents, pro-kinetic agents or laxatives.

- Subject plans to use another over-the-counter gas-relief product daily during the study period. Over-the-counter gas relief products may be used as rescue medication (their use will be captured by the study staff). If a subject is using a fiber supplement prior to starting the study, he/she may continue as long as the frequency and quantity remain stable throughout the study period.

- Subject has an allergy to wheat or fish or any of the other product ingredients (see section 2.5.4).

- Subject has two or more food allergies.

- Subject has a history of drug or alcohol abuse within the past 12 months.

- Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.

- Female subject of childbearing potential is unwilling to use an acceptable form of contraceptive device throughout the study period.

- Subject is pregnant, lactating, or planning to become pregnant during the study period.

- Subject is participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.

- Subject is deemed by the Investigator as an unsuitable candidate for receipt of an investigational dietary supplement, or unable to be followed up throughout the entire duration of the study.

- Subject is unable to comprehend the Informed Consent and research purpose.

- Subject is unable or unwilling to comply with the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
BC-130 (Gas Defense)
Product Dosing: Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food) Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish.
Placebo
Product Dosing: Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food) Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule

Locations

Country Name City State
Dominican Republic Latin American Research Santo Domingo
United States Miami Research Associates Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
Miami Research Associates Ganeden Biotech, Inc.

Countries where clinical trial is conducted

United States,  Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the effect of daily supplementation with GD as compared to placebo on intestinal gas symptoms as measured by the subscores of the GI Symptom Rating Scale (GSRS) and the subscores of the Severity of Dyspepsia Assessment (SODA). 4 weeks No
Primary Primary Safety Objective To determine if daily supplementation with GD is safe within the confines of this study as denoted by changes from baseline in blood pressure, heart rate, adverse events, and subjective remarks. 4 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT04682860 - Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide Phase 4
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02547857 - Transvaginal Pelvic Ultrasound in the ED N/A
Completed NCT02923245 - POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02676232 - DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families. N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Terminated NCT01410071 - Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction N/A
Terminated NCT01736280 - Evaluating and Treating Potential Research Participants With Digestive Disorders N/A
Enrolling by invitation NCT04104867 - Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy N/A
Completed NCT03574727 - Abdominal Cutaneous Nerve Entrapment Syndrome
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT05438654 - Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain N/A
Completed NCT06423586 - Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS N/A
Completed NCT03558009 - Epidemiological Analysis for Hereditary Angioedema Disease
Terminated NCT03148288 - Vitamin D Supplementation in IBS N/A
Completed NCT03708874 - Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
Withdrawn NCT04408872 - EUS vs EGD in Emergency Room Patients Referred for EGD N/A
Recruiting NCT02594774 - Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents N/A